Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06669754 · ClinicalTrials.gov registry record · Phase 3

Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE

A Phase 3 study of Hereditary Angioedema (HAE), sponsored by Pharvaris Netherlands B.V..

Active
Registry status
Phase 3
Development phase
81
Enrollment target
20
Study locations

NCT06669754: Active Phase 3 study of Hereditary Angioedema (HAE), sponsored by Pharvaris Netherlands B.V..

NCT06669754 is a Phase 3 study of Hereditary Angioedema (HAE) that is active but no longer recruiting, run by Pharvaris Netherlands B.V.. The registered enrollment target is 81 participants, above the 56-participant average among 7 other Hereditary Angioedema (HAE) trials with a reported enrollment target (45% higher). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06669754, a Phase 3 study of Hereditary Angioedema (HAE), is active but no longer recruiting, sponsored by Pharvaris Netherlands B.V..

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
81 participants
Enrollment target
20
Study locations

Study Summary

This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of once-daily orally administered deucrictibant extended-release tablet compared to placebo for prophylaxis to prevent angioedema attacks in participants aged ≥ 12 years with hereditary angioedema.

Conditions Studied

Hereditary Angioedema (HAE)

Interventions

  • DRUG Placebo
  • DRUG Deucrictibant

Study Locations (20)

Other

  • Study Site - Corrientes
  • Study Site - San Martín
  • Study Site - Santo André
  • Study Site - Sofia
  • Study Site - Sofia
  • Study Site - Edmonton
  • Study Site - Ottawa
  • Study Site - Grenoble
  • Study Site - Lille
  • Study Site - Berlin
  • Study Site - Frankfurt
  • Study Site - Hanover
  • Study Site - Hong Kong
  • Study Site - Budapest

California

  • Study Site - San Diego
  • Study site - Santa Monica
  • Study site - Walnut Creek

Arkansas

  • Study Site - Little Rock

Maryland

  • Study Site - Chevy Chase

Missouri

  • Study Site - St Louis

Trial Details

FieldValue
Enrollment Target 81 participants
Start Date 2024-12-01
Est. Completion 2026-08
Phase Phase 3
Pharvaris Netherlands B.V.

6 total trials

What the registry record for NCT06669754 still lists

NCT06669754 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 81 participants, a relatively small participant target, above the 56-participant average among 7 other Hereditary Angioedema (HAE) trials with a reported enrollment target (45% higher).

The record links to 1 condition, with Hereditary Angioedema (HAE) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06669754 names 20 study sites across 5 states, led by Other, California, Arkansas.

Frequently Asked Questions

What is clinical trial NCT06669754 about?

NCT06669754 is a clinical study titled "Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE". This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of once-daily orally administered deucrictibant extended-release tablet compared to placebo for prophylaxis to prevent angioedema attacks in participants aged ≥ 12 years with heredi...

What is the current status of trial NCT06669754?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 81 participants. The study started on 2024-12-01. Estimated completion is 2026-08.

What conditions does trial NCT06669754 study?

This clinical trial studies the following conditions: Hereditary Angioedema (HAE).

What interventions are being tested in trial NCT06669754?

The interventions under investigation include: Placebo (DRUG), Deucrictibant (DRUG).

Who is sponsoring clinical trial NCT06669754?

This trial is sponsored by Pharvaris Netherlands B.V., which has 6 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06669754 being conducted?

This trial has 20 study locations across Arkansas, California, Maryland, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Hereditary Angioedema (HAE)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04966481 · 81 participants · Phase 3

    Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor

  • NCT05109429 · 81 participants · NA

    Developing a Clinical Outcome Assessment for Opioid Craving

  • NCT05112601 · 81 participants · Phase 2

    Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma

  • NCT05305911 · 81 participants · Phase 2

    Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT06669754, the US trial registry maintained by the National Library of Medicine. NCT06669754 (small enrollment · wide site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.